Drug Trial Radar · NCT04493853
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,012
Actual
Start
Jul 13, 2020
Primary completion
Oct 7, 2024
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the combination of capivasertib plus abiraterone (+prednisone/prednisolone) plus ADT is superior to placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC characterised by PTEN deficiency with respect to radiographic progression-free survival (rPFS) per 1) Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for soft tissue and/or Prostate Cancer Working Group (PCWG3) for bone as assessed by the investigator 2) death due to any cause.
Conditions
- Hormone-Sensitive Prostate Cancer
Interventions
CapivasertibDrug
400 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
PlaceboOther
matched to capivasertib appearance (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
Abiraterone AcetateDrug
Administered orally as tablets at a dosage of 1000 mg daily. Administered continuously until criteria for discontinuation are met.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic Progression-free Survival (rPFS)Time frame: Tumor assessments every 16 weeks from randomisation until radiographic progression assessed by the investigator. The timing of the Primary analysis DCO for rPFS is approximately 49 months from the first subject randomized
Locations
323 sites in 32 countries. Site status is shown where the registry gives one.
Research Site
Tucson, Arizona
Research Site
Tucson, Arizona
Research Site
La Jolla, California
Research Site
Orange, California
Research Site
San Diego, California
Research Site
Denver, Colorado
Research Site
Lakewood, Colorado
Research Site
Norwich, Connecticut
Research Site
Fort Myers, Florida
Research Site
West Palm Beach, Florida
Research Site
Chicago, Illinois
Research Site
Geneva, Illinois
Research Site
Lisle, Illinois
Research Site
Baltimore, Maryland
Research Site
Detroit, Michigan
Research Site
Grand Rapids, Michigan
Research Site
Troy, Michigan
Research Site
Syracuse, New York
Research Site
The Bronx, New York
Research Site
Asheville, North Carolina
Research Site
Durham, North Carolina
Research Site
Columbus, Ohio
Research Site
Lancaster, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Charleston, South Carolina
Research Site
Myrtle Beach, South Carolina
Research Site
Chattanooga, Tennessee
Research Site
Houston, Texas
Research Site
Norfolk, Virginia
Research Site
Roanoke, Virginia
Research Site
Seattle, Washington
Research Site
Madison, Wisconsin
Research Site
Berazategui, Argentina
Research Site
Buenos Aires, Argentina
Research Site
CABA, Argentina
Research Site
CABA, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
La Plata, Argentina
Showing 40 of 323 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.